Drug Trial Radar · NCT07677384
A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia Disorder
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Jun 30, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this open-label phase Ⅲ study is to evaluate the safety of HS-10506 on the incidence and severity of adverse events (AE), serious adverse events (SAE), adverse events of special interest (AESI) in Chinese adult participants with insomnia disorder.
Conditions
- Insomnia Disorder
Interventions
HS-10506Drug
HS-10506 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AE)Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
- Incidence and severity of serious adverse events (SAE)Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
- Incidence and severity of adverse events of special interest (AESI)Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.